Pain has a serious impact on human life, and the existing analgesic drugs are not ideal and will produce toxicity that greatly reduces the quality of life. Therefore, it is necessary to develop new drugs that are safe and effective and do not produce drug dependence. CD BioSciences is committed to providing comprehensive peptide mimetic development services with analgesic activity to help global customers make greater progress in basic research and drug discovery of pain related diseases.
Overview of Pain
Pain is the most common disease in the world, yet relative to other medical conditions, there are relatively few resources available to study pain, its causes and effects of treatment. And most of the current drug treatment is not effective and has certain toxicity, so it cannot be used for a long time. New knowledge has emerged about the causes of pain and its relationship to tolerance, addiction, and other conditions associated with current medical treatments, creating an urgent need for new effective and safe treatments for pain.
Disadvantages of Existing Analgesics
At present, opioids and non-steroidal anti-inflammatory drugs are commonly used to treat pain. They have unacceptable toxicity and drug dependence, especially during long-term use. Natural endogenous peptides based on human and other animals, such as enkephalin, endorphin, dynorphin, etc., have been proven to have effective analgesic properties in animal acute and long-term pain models, and they greatly reduce or have no toxicity of current analgesic drugs. While short biological half-lives, low oral bioavailability, and poor metabolic stability limit the potential of unmodified peptides as drug candidates, the unmatched selectivity and potency of these peptides are highly desirable in drug design.
Based on this, the development of peptidomimetics on the basis of natural active peptides to solve the deficiencies in making up their drugs will have important drug development significance.
Fig. 1 Endogenous opioid peptide expression and levels following exposure to drugs of abuse. (Conway, et al., 2022)
Our Services
CD BioSciences provides comprehensive peptidomimetic development services with analgesic activity.
Using our PepDomTM platform, peptide side chain changes, amino acid extension, removal, replacement and peptide skeleton modification are carried out on the basis of natural peptides to obtain new multivalent, multi-functional targeted peptidomimetics, which can effectively treat long-term and neuropathic pain without serious side effects of current analgesic toxicity and will not produce tolerance for long-term use.
Our specific services include but are not limited to:
| Services | Types |
Examples |
| Development of peptidomimetics targeting different opioid receptors |
MOR agonist |
Dmt-DALDA |
| DOR agonist |
UFP-512 |
| DOR antagonist (also in combination with MOR agonist activity) |
TY005 |
| KOR agonist |
CR665 |
| KOR antagonist |
Zyklophin |
| Development of Opioid Peptide Analogs |
Dermorphin and endomorphin analogs |
Dmt-DALDA |
| Dmt-Tic derivatives |
UFP-512 |
| Dynorphin analogs and related peptides |
SK-9709 |
| Glycosylated peptide |
MMP-2200 |
| Pegylated peptides |
PEG-DPDPE |
| Novel opioid peptides |
c[YpwFG] |
| Development of Non-Opioid Peptidomimetics |
Analgesic peptidomimetics targeting ion channels |
Ssm6A |
| Analgesic peptidomimetics targeting non-opioid GPCRs |
DD04107, Hemopressin |
| Analgesic peptidomimetics targeting protein-protein interactions |
TAT-CBD3, TRP-p5 |
| Other analgesic peptidomimetics |
α7 nAChR PAM |
Advantages of Our Peptidomimetics
High Stability
Low or No Biological Toxicity
No Drug Dependence
Able to Cross Membrane Barriers
CD BioSciences focuses on developing peptidomimetics with analgesic activity. As long as you provide the objectives and research directions you are interested in, our professional team will immediately provide you with professional solutions and measures. Welcome to contact us for the best solution.
References
- Hruby, V. J. (2019). Multivalent Peptide and Peptidomimetic Ligands for the Treatment of Pain without Toxicities and Addiction. Peptides, 116, 63-67.
- Giri, A. K., & Hruby, V. J. (2013). Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain. Expert Opinion on Investigational Drugs, 23(2), 227–241.
- Conway, S. M., Mikati, Marwa. O., Al-Hasani, R. (2022). Challenges and new opportunities for detecting endogenous opioid peptides in reward. Addiction Neuroscience, 2, 100016.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
